# NRW.Venture

> NRW.Venture is a VC fund backing Biotechnology, Apps and SaaS. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Jun 2026
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nrw-bank
- X (Twitter): https://twitter.com/NRWBANK
- Website: https://www.nrwbank.de/en

NRW.Venture is a source of funding for new, innovative, and often technology-focused businesses that do not have easy access to loans.

## Contacts

5 contacts available for NRW.Venture. Shizune tracks 1 team members at NRW.Venture. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nrw-venture?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 25% |
| Apps | 1 | 13% |
| SaaS | 1 | 13% |
| Battery | 1 | 13% |
| Medical | 1 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Series A | 3 | 38% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 5 | 63% |
| Switzerland | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Eckhard Forst | Chairman of the Managing Board | 0 | https://shizune.co/investors/profile/eckhard-forst |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jupus | As the first legal AI secretary in Europe, JUPUS automates the entire process from initial client contact to the complete file. Lawyers are supported by an AI chatbot, an online appointment booking tool, and an AI platform that automatically collects and processes inquiries, information, and documents, facilitating automated communication withclients. | $14.8M | Series A | Jun 23, 2026 |  |
| iDEL Therapeutics | iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M | Seed | Mar 17, 2026 |  |
| clockin | If you want to track your employees' working hours easily and in a legally compliant manner, clockin is the right choice. The multi-award-winning app reduces paperwork and manual effort to a minimum. The app can be installed on smartphones or as a tablet terminal in just a few minutes. Companies can add their employees just as easily and starttime tracking right away. The timesheets for individual employees, which are required for payroll accounting, are created automatically by clockin. In addition, the clockin app offers further functions, such as the option of a team calendar, requesting absences, tracking time on specific projects, obtaining signatures and thus every manual process is mapped digitally. | $11.7M | Series A | Sep 30, 2025 |  |
| EvlaBio | EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical). | $24.6M | Seed | Jul 07, 2025 |  |
| Vytal | Vytal is a provider of software-enabled reusable packaging solutions to eliminate single-use packaging waste in the food and beverage industry. It offers a reusable container system and container management software to facilitate sustainable takeaway and delivery services, serving restaurants, supermarkets, caterers, canteens, and event organizers. | $15.5M |  | Mar 11, 2025 |  |
| Refoxy Pharma | Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. | $9.6M | Seed | Dec 04, 2024 |  |
| Refoxy Pharma | Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. | $9.6M | Seed | Dec 04, 2024 |  |
| Cylib | Cylib provides technology for recycling lithium-ion batteries into usable raw materials, turning battery waste and production scrap into materials like lithium, graphite, nickel, cobalt, and manganese for reuse in battery and industrial supply chains. Their proprietary process focuses on the holistic recovery of all battery components, utilizingwater-based methods to minimize chemical use and reduce environmental impact. Cylib operates an integrated end-to-end recycling workflow that includes discharge, material separation, and refinement for reintegration into manufacturing processes. The company’s approach supports circular material flows and aims to strengthen supply chains for battery producers and related industrial partners. | $59.9M | Series A | May 15, 2024 |  |

8 of 8 investments shown.

## Co-investors
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 4 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 3 deals together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 2 deals together
- [10x Founders](https://shizune.co/investors/profile/10x-founders) — VC Fund, 1 deal together
- [Acton Capital](https://shizune.co/investors/profile/acton-capital-partners) — VC Fund, 1 deal together
- [AdBio partners](https://shizune.co/investors/profile/advent-france-biotechnology) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [CleanTech VC Funds in Germany](https://shizune.co/investors/cleantech-vc-funds-germany)

## FAQ

### What does NRW.Venture invest in?

NRW.Venture invests primarily in Biotechnology, Apps and SaaS startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NRW.Venture?

Public channels for NRW.Venture include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NRW.Venture?

The team at NRW.Venture includes Eckhard Forst (Chairman of the Managing Board). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co